Halozyme (HALO) posts Q3 Loss of 16c, Beats by 2c
More News related to HALO
- ProMetic and Halozyme Enter Into Long-Term Supply Agreement
- Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme
- Halozyme (HALO) posts Q3 Loss of 16c, Beats by 2c
- Halozyme Therapeutics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/06: American International (AIG), Scripps (SNI), Suncor Energy (SU), Blackstone Group (BX) Report
More News related to Earnings
- Spectrum Pharma (SPPI) Files $250M Mixed Shelf
- Bank of Kentucky Financial (BKYF) Files $50M Mixed Shelf
- Nanophase Tech. (NANX) Files 847K Common Shelf for Selling Shareholders
- Altra Holdings (AIMC) Closes $210M Senior Notes Offering; Enters Into Revolving Credit Facility; Subsidiary Tenders $167.9M of Senior Notes
- Sigma Designs (SIGM) Files 3.93M Share Shelf for Common Stock
Halozyme (NASDAQ: HALO) reports Q3 loss of $0.16, 2 cents better than the analyst estimate of ($0.18). Revenue for the quarter was $3.03 million, which compares to the estimate of $3.11 million.
Related Categories
EarningsStocks Mentioned
-0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
